When Commerce Learns to Feed Half an Appetite

McDonald's recently acknowledged what was once unthinkable: a growing segment of customers arrive already half-full. The culprit isn't competition or changing tastes, but GLP-1 medications like Ozempic and Wegovy, now used by roughly 12% of American adults—double the rate from 18 months ago. CEO Chris Kempczinski told investors the company is monitoring this "trend" closely, testing protein-rich items and bunless burgers for customers whose pharmaceutical regimen has effectively outsourced appetite control.

What's striking isn't that corporations adapt—they always do. It's the speed and seamlessness with which the market absorbs medical intervention into human desire as simply another consumer segment to serve. Shake Shack offers lettuce-wrapped burgers. Conagra labels frozen meals "GLP-1 Friendly." A Cuban restaurant in Orlando redesigned its ropa vieja with a weight-loss specialist. No one pauses to ask what we're normalizing.

The Christian tradition has always understood that our hungers reveal us—that what we desire and how we manage desire shapes our souls. Fasting was never primarily about weight loss but about learning that we are not defined by our appetites, that we can say no to good things for the sake of better ones. It assumed hunger was something to be disciplined by community, liturgy, and practice—not chemically regulated and then commercially optimized.

When pharmaceutical companies suppress appetite and restaurants race to profit from that suppression, we've closed a loop that may be efficient but asks nothing of us. We never have to sit with our actual hunger, never have to ask why we eat, never have to practice the freedom that comes from self-restraint. We've made desire itself another thing to be managed by professionals and monetized by markets. The real question isn't what McDonald's will serve next. It's what happens to us when even our hunger is no longer our own.